Tarsus (TARS) Q4 2025 earnings review
XDEMVY Sales Surge 128%; Profitability Now in Sight
Tarsus delivered a blowout fourth quarter. XDEMVY revenues accelerated to $151.7M, driven by 130,000 bottles dispensed. The massive Direct-to-Consumer (DTC) advertising bet is paying off: unaided awareness hit 25%, and the resulting volume surge nearly wiped out the bottom-line deficit, narrowing net loss to just $8.4 million. Management is so confident they upgraded XDEMVY peak sales potential to over $2 billion. Operating leverage is firmly taking hold as revenue growth now outpaces aggressive marketing spend.
🐂 Bull Case
Bottles dispensed reached 130,000 in Q4, up from 103,000 in Q3 and 58,500 a year ago. Demand is accelerating steadily, proving Demodex blepharitis is a massive, highly responsive market.
Despite a massive jump in SG&A to fund TV campaigns, top-line growth is outrunning expenses. Net loss reversed its trajectory, shrinking from $25.1M in 25Q1 to just $8.4M in 25Q4.
🐻 Bear Case
SG&A expenses nearly doubled YoY to $130.7M in Q4. Tarsus is buying this growth at a high price, meaning any future slowdown in consumer response could immediately compress margins.
The entire $451M revenue base relies exclusively on XDEMVY. Pipeline assets for Ocular Rosacea and Lyme disease remain in Phase 2, offering no near-term diversification.
⚖️ Verdict: 🟢
Bullish. Tarsus is executing a flawless launch playbook. XDEMVY volume is accelerating, the gross-to-net discount is improving, and the company is on the precipice of generating positive net income. The aggressive ad spend is fully justified by the returns.
Key Themes
DTC Campaign Yields Positive ROI
The massive Direct-to-Consumer (DTC) advertising campaign across streaming and network TV is clearly working. Unaided patient awareness of Demodex blepharitis has skyrocketed to approximately 25%, up from just 2% before the campaign. This patient-led demand is the primary driver accelerating bottle volume quarter over quarter.
Runaway SG&A Expenditures
While revenue is growing, the cost to acquire it remains astronomical. SG&A expenses hit an eye-watering $130.7M in Q4, up from $69.0M a year ago. $31.2M of this increase was directly tied to commercial and marketing costs. While the trend is currently stable because revenue is covering the bill, this level of burn requires flawless ongoing commercial execution.
Gross-to-Net (GTN) Discount Continues to Improve
Pricing power is accelerating. Management successfully secured greater payer coverage in 2025 (maintaining >90% covered lives) while improving the GTN discount to ~44% in Q4 (from 47% in Q1). Sustaining this premium pricing maximizes the flow-through of new volume to the bottom line.
Pipeline Validates 'Category Creation' Blueprint
Tarsus is systematically targeting parasitic root causes. The initiation of the Phase 2 trial for TP-04 (Ocular Rosacea) and the planned Q2 2026 Phase 2 for TP-05 (Lyme Disease) proves the company is pivoting from a single-drug story to an integrated platform for mite/tick eradication.
International Expansion Timelines Stretching
Global growth remains a waiting game. The European preservative-free formulation isn't expected to see potential approval until 2027. China is slated for 2026 via a partner, and Japan remains in 'ongoing discussions.' Domestic US sales must carry the entire weight of the valuation for at least the next 12-18 months.
Other KPIs
Stable. Gross margins remained completely flat at 93% for both Q4 and the full year, identical to 2024 levels. Cost of sales is driven efficiently by manufacturing and royalty payments, proving XDEMVY scales exceptionally well on a unit economics basis.
Accelerating. Cash, cash equivalents, and marketable securities grew significantly from year-end 2024 ($291M), aided by a public offering earlier in the year. With net losses shrinking to just $8.4M this quarter, Tarsus has effectively eliminated any near-term dilution risk to fund operations.
Guidance
Accelerating. Management provided a major qualitative upgrade, stating they now see a clear path to peak sales exceeding $2 billion. This is a massive step up from early launch days when the goal was closer to $1 billion.
Stable. The company initiated the Phase 2 trial for lotilaner sterile ophthalmic gel and expects topline data in the first half of 2027, locking in a multi-year catalyst timeline.
Stable. The investigational oral tablet designed to kill ticks and prevent Lyme disease transmission is scheduled to begin Phase 2 testing in the second quarter of 2026.
Key Questions
SG&A Ceiling vs Profitability
With SG&A hitting $130M in Q4, are we nearing the ceiling of the DTC investment, or will spend continue to scale linearly with revenue through 2026? When do you expect to cross into positive net income?
Retreatment Durability
Of the 130,000 bottles dispensed in Q4, what percentage were recurring refills from earlier patient cohorts versus first-time new prescriptions?
Lyme Disease Partnership
You previously mentioned that the Lyme disease program (TP-05) might require a larger partner for Phase 3. As you approach Phase 2 in Q2 2026, are partnership discussions advancing, or do you plan to fund this phase entirely in-house?